ACAD ACADIA Pharmaceuticals, Inc. shares are down by 5.58% Ends Trading
ACAD ACADIA Pharmaceuticals, Inc.
Acadia Pharmaceuticals said it is likely to exercise an option to co-market its psychosis drug in the United States, and that the experimental product has strong sales potential. Acadia in May announced a deal under which Biovail Corp will help develop its drug, pimavanserin, and sell it in North America, with Acadia having an option to co-market the product in the same market.
StockEinstein.com offers free trading alerts on stocks about to run. To sign up for our free alert service please click here www.stockeinstein.com or scroll to bottom of this page to sign up.
ABOUT ACADIA Pharmaceutical
ACADIA Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders. It focuses on developing a portfolio of its four advanced product candidates, including Pimavanserin, which is in phase III development for Parkinson’s disease psychosis; and a product candidate in phase II for chronic pain and a product candidate in phase I for glaucoma, each in collaboration with Allergan, Inc., as well as ACP-106 in IND-track development for neuropsychiatry and sleep indications. Pimavanserin is also in a phase II trial as a co-therapy in schizophrenia and in a proof-of-concept clinical study for sleep maintenance insomnia. ACADIA Pharmaceuticals development pipeline also consists of ACP-105 for endocrine indications in IND-track development stage; Serotonin program for neuropsychiatry and sleep indications in preclinical stage; pro-cognitive antipsychotic (PCAP) program for schizophrenia in preclinical stage; Muscarinic program for neuropsychiatry and other indications; and two series of compounds for Parkinson’s disease.
About StockEinstein
StockEinstein.com uses proprietary technologies coupled with years of experience to uncover stocks we feel have the greatest potential for breakout performance. We utilize not only software, but time tested criteria to uncover these potential winners. When these benchmarks are reached or exceeded, our subscribers are immediately notified.
Disclaimer: Full disclaimer at http://StockEinstein.com/disclaimer.php
IMPORTANT: Never invest in any stock featured in any press release, email or website unless you can afford the loss of your entire investment. Stocks and particularly penny stocks have the possibility for dramatic gains, and also losses. Neither StockEinstein, nor any of its affiliates are registered investment advisors or broker dealers.
Thank you for your interest in Findit News. A member of the Findit News team will contact you soon to show you how you can take your marketing to the next level with press releases on Findit.
